Second-line chemotherapy and its evaluation in small cell lung cancer

Cancer Treatment Reviews

Volumn 25, Issue 4, 1999, Pages 199-206

  Huisman, C ^b   Postmus, P E ^b   Giaccone, G ^a   Smit, E F ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; MESNA; METHOTREXATE; NAVELBINE; PACLITAXEL; TENIPOSIDE; THIOTEPA; TOPOTECAN; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; HUMAN; LUNG SMALL CELL CANCER; PATIENT SELECTION; QUALITY OF LIFE; TREATMENT PLANNING;

EID: 0032840016     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1999.0125     Document Type: Article

References (42)

1. Seifter EJ and Idhe D. C. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol. 15:1988;278-299.
2. Elias A. D. Small cell lung cancer, state-of-the-art therapy in 1996. Chest. 112:1997;251S-258S.
3. Johnson, DH. Treatment of relapsed small cell lung cancer. Lung Cancer, 11.
4. Andersen M., Kristjansen PEG and Hansen H. H. Second-line chemotherapy in small cell lung cancer. Cancer Treat Rev. 17:1990;427-436.
5. Batist G., Ihde D. C., Zabell A., Lichter A. S., Veach S. R., Cohen M. H., Carney DN and Bunn P. A. Small cell carcinoma of the lung: reinduction therapy after late relapse. Ann Intern Med. 98:1983;472-474.
6. Giaccone G., Ferrati P., Donadio M., Testore F and Calciati A. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol. 23:1987;1697-1699.
7. Postmus P. E., Berendsen H. H., Van Zandwijk N., Splinter T. A. W., Burghouts JThM and Bakker W. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol. 23:1987;1409-1411.
8. Giaccone G., Donadio M., Bonardi G., Testore F and Calciati A. Teniposide in the treatment of small cell lung cancer: the influence of prior chemotherapy. J Clin Oncol. 6:1988;1264-1270.
9. Johnson D. H., Greco F. A., Strupp J., Hande KR and Hainsworth J. D. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: A phase II trial. J Clin Oncol. 8:1990;1613-1617.
10. Giaccone G., Dalesio O., McVie G. J., Kirkpatrick A., Postmus P. E., Burghouts J. ThM., Bakker W., Koolen M. G. J., Vendrik C. P. J., Roozendaal K. J., Planting A. S. T., Van Zandwijk N., Ten Velde GJM and Splinter T. A. W. Maintenance chemotherapy in small cell lung cancer: long term results of a randomized trial. J Clin Oncol. 11:1993;1230-1240.
11. Giaccone G., Donadio M., Bonardi G., Testore F and Calciati A. Teniposide in the treatment of small cell lung cancer: the influence of prior chemotherapy. J Clin Oncol. 6:1988;1264-1270.
12. Smit E. F., Fokkema E., Biesma B., Groen H. J. M., Snoek W and Postmus P. E. A phase II study of paclitaxel in heavily pretreated patients with small cell lung cancer. Br J Cancer. 77:1998;347-351.
13. Perez-Solar R., Glisson B. S., Lee J. S., Fossella F. V., Murphy W. K., Shin DM and Hong W. K. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase 1 poison topotecan. J Clin Oncol. 14:1996;2785-2790.
14. Berendsen H. H., De Leij L., De Vries, Mesander G., Mulder N. H., De Jong B., Buys C. H., Postmus P. E., Poppema S and Sluiver H. J. Characterisation of three small cell lung cancer cell lines established from one patient during clinical follow-up. Cancer Res. 48:1988;6891-6899.
15. De Vries E. G. E., Meijer C., Timmer-Bosscha H., Berendsen H. H., De Leij L and Buys C. H. Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up. Cancer Res. 47:1989;4175-4178.
16. Poupon M. F., Arvelo F., Goguel A. F., Bourgeais Y., Jacrot M., Hanania N., Arrigada R and Le Chevalier T. Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates. J Natl Cancer Inst. 85:1993;2023-2029.
17. Moore TD and Korn E. L. Phase II trial design considerations for small cell lung cancer. J Natl Cancer Inst. 84:1992;150-154.
18. Grant S. C., Gralla R. J., Kris M. G., Orazem J and Kitsis E. A. Single-agent chemotherapy trials in small-cell lung cancer, 1970-1990: the case for studies in previously treated patients. J Clin Oncol. 10:1992;484-498.
19. Souhami R. L., Spiro S. G., Rudd R. M., Ruiz de Elvira M. C., James L. E., Gower N. H., Lamont A and Harper P. G. Five-day oral etoposide treatment for advanced small cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst. 89:1997;577-580.
20. Girling D. J. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small cell lung cancer: a stopped multicentre trial. Lancet. 348:1996;563-566.
21. Groen H. J. M., Fokkema E., Biesma B., Kwa H. B., Van Putten J., Postmus PE and Smit E. F. Paclitaxel and carboplatin in the treatment of small cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide. A non-cross resistant schedule. J Clin Oncol. 17:1999;927-932.
22. Masuda N., Matsui K., Negoro S., Takifuji N., Takeda K., Yana T., Kobayashi M., Hirashima T., Kusunoki Y., Ushijima S., Kawase I., Tada T., Sawaguchi H and Fukuoka M. Combination of Irinotecan and Etoposide for treatment of refractory or relapsed small cell lung cancer. J Clin Oncol. 16:1998;3329-3334.
23. Kubota K., Nishiwaki Y., Kakinuma R., Hojo F., Marsumoto T., Ohmatsu H., Sekine I., Yokozaki M., Goto K., Ebi N and Kodama T. Dose-intensive weekly chemotherapy for treatment of relapsed small cell lung cancer. J Clin Oncol. 1997;15.
24. Faylona E., Loehrer P., Einhorn L., Ansari R., McClean J and Williams S. A phase II study of daily oral VP-16 + ifosfamide + cisplatin for previously treated small cell lung cancer: a Hoosier oncology group trial. J Clin Oncol. 13:1995;1209-1214.
25. Einhorn LH and Loehrer P. J. Hoosier oncology group studies in extensive and recurrent small cell lung cancer. Semin Oncol. 22:1995;28-31.
26. Postmus P. E., Smit E. F., Kirkpatrick A and Splinter T. A. W. Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer. 29A:1993;204-207.
27. Falk S. J., Maughan T. S., Laurance V. M., Lamont A., Boote D., Ford J. M., Osborne RJ and Bleehan N. M. Phase II study of carboplatin and adriamycin as second-line chemotherapy in small cell lung cancer. Clin Oncol. 5:1993;85-88.
28. Albain K. S., Crowly J. J., Hutchins L., Gandara D., O'Bryan R. M., Von Hoff D. D., Griffin B and Livingston R. B. Predictors of survival following relapse or progression of small cell lung cancer. Cancer. 72:1993;1184-1191.
29. Postmus P. E., Smit E. F., Berendsen HH and Haaxma-Reiche H. Second-line carboplatin-based chemotherapy for small cell lung cancer: the Groningen experience. Sem Oncol. 19:1992;17-23.
30. O'Bryan R. M., Crowley J. J., Kim P. N., Epstein R. B., Neilan B., Coltman C. A., Stuckey WJ and Pazdur R. Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine and cyclophosphamide for salvage treatment in small cell lung cancer. Cancer. 65:1990;856-860.
31. Smit E. F., Berendsen H. H., De Vries E. G. E., Mulder NH and Postmus P. E. A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer. Cancer Chemother Pharmacol. 25:1989;202-204.
32. Spiro S. G., Souhami R. L., Geddes D. M., Ash C. M., Quinn H., Harper P. G., Tobias J. S., Partridge M and Eraut D. Duration of chemotherapy in small cell lung cancer: a cancer research trial. Br J Cancer. 59:1989;578-583.
33. Von Pawel, J. Depierre, A. Hans, K. Moro, D. Clark, P. I. Gatzemeier, U. Paillot, N. Scheithauer, W. Carmichael, J. Santoro, A. Ross, G. Hearn S and Marangolo, M. Evaluation of topotecan (hycampthin): in relapsed small cell lung cancer Submitted 1991.
34. Von Pawel J., Schiller J. H., Shepherd F. A., Fields S. Z., Kleisbauer J. P., Chrysson N. G., Stewart D. J., Clark P. I., Palmer M. C., Depierre A., Carmichael J., Krebs J. B., Ross G., Lane SR and Gralla R. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for treatment of recurrent small cell lung cancer. J Clin Oncol. 17:1999;657-667.
35. Ardizzoni A., Hansen H., Dombernowsky P., Gamucci T., Kaplan S., Postmus P. E., Giaccone G., Schaefer B., Wanders J and Verweij J. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol. 15:1997;2090-2096.
36. Perez-Solar R., Glisson B. S., Lee J. S., Fossella F. V., Murphy W. K., Shin DM and Hong W. K. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol. 14:1996;2785-2790.
37. Fusure K., Kubota K., Kawahara M., Takada M., Kimura I., Fuji M., Hasegawa K., Yoshida K., Nakajima S., Ogura T and Niitani H. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology. 53:1996;169-172.
38. Smyth J. F., Smith I. E., Sessa C., Schoffski P., Wanders J., Franklin H and Kaye S. B. Activity of docetaxel (taxotere) in small cell lung cancer. Eur J Cancer. 30A:1994;1058-1060.
39. Jassem J., Karnicka-Mlodkowska H., Van Pottelsberghe Ch, Van Glabbeke M., Noseda M. A., Gozzelino F., Planting A and Van Zandwijk N. Phase II study of vinorelbine (navelbine) in previously treated small cell lung cancer patients. Eur J Cancer. 29A:1993;1720-1722.
40. Masuda N., Fukuoka M., Kusunoki Y., Matsui K., Takifuji N., Kudoh S., Negoro S., Nishioka M., Nakagawa K and Takada M. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 10:1992;1225-1229.
41. Tummarello D., Guidi F., Torresi U., Dazzi C and Cellerino R. Teniposide (VM-26) as second-line treatment for small cell lung cancer. Anticancer Res. 10:1990;397-400.
42. Tummarello D., Guidi F., Di Furia L., Gramazio A., Menichetti E and Cellerino R. A phase II study with teniposide (VM-26) in patients with progressed or relapsed small cell lung cancer. J of Chemother. 1:1989;64-67.